Kumaraguru Raja
Stock Analyst at Brookline Capital
(n/a)
# 4,867
Out of 4,868 analysts
15
Total ratings
7.69%
Success rate
-51.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PALI Palisade Bio | Maintains: Buy | $16 | $0.62 | +2,491.93% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $1.30 | +592.31% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $1.77 | +351.98% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $14.66 | +582.13% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $1.71 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.25 | +61,024.69% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $3.00 | +400.00% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $3.07 | +584.04% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $33.84 | +165.96% | 1 | Dec 9, 2022 | |
| VERU Veru Inc. | Maintains: Buy | $29 → $31 | $0.62 | +4,875.12% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,360 | $0.67 | +501,767.06% | 1 | Sep 21, 2021 |
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $0.62
Upside: +2,491.93%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $1.30
Upside: +592.31%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $1.77
Upside: +351.98%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $14.66
Upside: +582.13%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.71
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.25
Upside: +61,024.69%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $3.00
Upside: +400.00%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $3.07
Upside: +584.04%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $33.84
Upside: +165.96%
Veru Inc.
May 18, 2022
Maintains: Buy
Price Target: $29 → $31
Current: $0.62
Upside: +4,875.12%
Sep 21, 2021
Initiates: Buy
Price Target: $3,360
Current: $0.67
Upside: +501,767.06%